1-4 of 4
Diego Bellido
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy of a Connected Insulin Pen Cap in People With Noncontrolled Type 1 Diabetes: A Multicenter Randomized Clinical Trial

Fernando Gomez-Peralta, Cristina Abreu, Elsa Fernández-Rubio, Laura Cotovad, Pedro Pujante, Sonia Gaztambide, Diego Bellido, Edelmiro Menéndez Torre, Santiago Ruiz-Valdepeñas, Hugo Bello, Xoan Valledor, Jesús Pérez-González, Luis Ruiz-Valdepeñas
Journal: Diabetes Care
Diabetes Care 2023;46(1):206–208
https://doi.org/10.2337/dc22-0525
Published: 21 December 2022
View articletitled, Efficacy of a Connected Insulin Pen Cap in People With Noncontrolled Type 1 Diabetes: A Multicenter Randomized Clinical Trial
Open the PDF for Efficacy of a Connected Insulin Pen Cap in People With Noncontrolled Type 1 Diabetes: A Multicenter Randomized Clinical Trial in another window
Journal Articles

Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39: 1972–1980

Vanita R. Aroda, Julio Rosenstock, Carol Wysham, Jeffrey Unger, Diego Bellido, Guillermo González-Gálvez, Akane Takami, Hailing Guo, Elisabeth Niemoeller, Elisabeth Souhami, Richard M. Bergenstal, on behalf of the LixiLan-L Trial Investigators
Journal: Diabetes Care
Diabetes Care 2017;40(6):809
https://doi.org/10.2337/dc17-er06d
Published: 20 April 2017
View articletitled, Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39: 1972–1980
Open the PDF for Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39: 1972–1980 in another window
Journal Articles

Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial

Graydon S. Meneilly, Christine Roy-Duval, Hasan Alawi, George Dailey, Diego Bellido, Carlos Trescoli, Helard Manrique Hurtado, Hailing Guo, Valerie Pilorget, Riccardo Perfetti, Hamish Simpson, on behalf of the GetGoal-O Trial Investigators
Journal: Diabetes Care
Diabetes Care 2017;40(4):485–493
https://doi.org/10.2337/dc16-2143
Published: 10 February 2017
View articletitled, Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial
Open the PDF for Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial

Vanita R. Aroda, Julio Rosenstock, Carol Wysham, Jeffrey Unger, Diego Bellido, Guillermo González-Gálvez, Akane Takami, Hailing Guo, Elisabeth Niemoeller, Elisabeth Souhami, Richard M. Bergenstal, on behalf of the LixiLan-L Trial Investigators
Journal: Diabetes Care
Diabetes Care 2016;39(11):1972–1980
https://doi.org/10.2337/dc16-1495
Published: 20 September 2016
View articletitled, Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial
Open the PDF for Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial in another window
Includes: Supplementary data